Hematologic Tests
Conditions
Keywords
Hematocrit, Plasma volume variation, Interval walking training, Lactate dehydrogenase, Obesity
Brief summary
The goal of this clinical trial is to to compare the effects of high (HIIWT) versus moderate-intensity interval walking training (MIIWT) on body composition, plasma volume variations (PVV), hematological parameters, muscle damage and aerobic capacity in overweight/obese postmenopausal women. The main question it aims to answer is:Does HIIWT and MIIWT improve kidney function markers in this population? Researchers will compare HIIWT to MIIWT and to non-training intervention(designed to control group) to see if the training program at different intensities work to improve kidney function markers. Participants in HIIWT group will: perform a 8-week HIIWT program, three sessions per week (5 repetitions of 6-min-walking-test (6MWT) at 90-110% of 6MWTdistance measured at baseline, interspersed by 6-min of active recovery between repetitions). Participants in MIIWT group will: perform a 8-week MIIWT program, three sessions per week (5 repetitions of 6-min-walking-test (6MWT) at 60-80% of 6MWTdistance measured at baseline, interspersed by 6-min of active recovery between repetitions). Participants in control group will : not perform any physical training and maintain their usual daily activities.
Detailed description
In obese postmenopausal women, hematological disturbances, reduced plasma volume, and elevated muscle damage biomarkers are associated with impaired oxygen delivery, reduced aerobic capacity, and increased risks of cardiovascular disease, sarcopenia, and functional decline. While responses to exercise are well documented in young healthy individuals, evidence in this high-risk population remains scarce. The purpose is to compare the effects of high (HIIWT) versus moderate-intensity interval walking training (MIIWT) on body composition, plasma volume variations (PVV), hematological parameters, muscle damage and aerobic capacity in overweight/obese postmenopausal women.Thirty-two overweight/obese postmenopausal women were randomly assigned to HIIWT (n = 11), MIIWT (n = 11), or control (CON, n = 10) groups. HIIWT and MIIWT groups performed intermittent walking at 90-110% and 60-80% of the 6-min-walking-test distance, respectively, 3 times/week for 8 weeks (60 min/session). Body composition, hematological and muscle damage markers, and 6 min walk test (6MWT) were assessed pre- and post-intervention. PVV was calculated after eight weeks under third conditions (HIIWT, MIIWT and CON).
Interventions
BEHAVIORALHigh intensity interval walking training
High intensity intermittent walking training for a period of 8 weeks. The intensity of the training is 90 to 110% of 6MWTdistance. The frequency of the training is three times a week
BEHAVIORALModerate-intensity interval walking training
Moderate intensity intermittent walking training for a period of 8 weeks. The intensity of the training is 60 to 80% of 6MWTdistance. The frequency of the training is three times a week
Sponsors
Wissal Abassi
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
45 Years to 59 Years
Healthy volunteers
No
Inclusion criteria
* Age range of 45-59 years. * Postmenopausal women (cessation of menses for at least 12 consecutive months). * Body mass index (BMI) ≥ 25 kg/m2. * Body weight remained constant (±2 kg) during the past 3 months. * Stable eating habits and physical activity for at least 3 months. * Sedentary lifestyle (exercise less than 1h/week).
Exclusion criteria
* Medical contraindications to physical activity, diagnosed metabolic, hormonal, orthopedic, or cardiovascular conditions. * Current use of hormone replacement therapy or any prescribed medication.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Erythrocytes | At baseline and at week 9 (after the eight weeks of the training intervention). | Blood levels of erythrocytes were collected from a blood sample (5 ml) and analyzed using a multichannel automated hematology analyzer (XN450; Sysmex, Norderstedt, Germany). |
| Hemoglobin | At baseline and at week 9 (after the eight weeks of the training intervention). | Blood levels of hemoglobin were collected from a blood sample (5 ml) and analyzed using a multichannel automated hematology analyzer (XN450; Sysmex, Norderstedt, Germany). |
| Hematocrit | At baseline and at week 9 (after the eight weeks of the training intervention). | Blood levels of hematocrit were collected from a blood sample (5 ml) and analyzed using a multichannel automated hematology analyzer (XN450; Sysmex, Norderstedt, Germany). |
| Mean corpuscular volume | At baseline and at week 9 (after the eight weeks of the training intervention). | Blood levels of mean corpuscular volume were collected from a blood sample (5 ml) and analyzed using a multichannel automated hematology analyzer (XN450; Sysmex, Norderstedt, Germany). |
| Mean corpuscular hemoglobin content | At baseline and at week 9(after the eight weeks of the training intervention) | Description: Blood levels of mean corpuscular hemoglobin content were collected from a blood sample (5 ml) and analyzed using a multichannel automated hematology analyzer (XN450; Sysmex, Norderstedt, Germany). Time Frame: At baseline and at week 9 (after the eight weeks of the training intervention) |
| Mean hemoglobin concentration | At baseline and at week 9 (after the eight weeks of the training intervention) | Blood levels of mean hemoglobin concentration were collected from a blood sample (5 ml) and analyzed using a multichannel automated hematology analyzer (XN450; Sysmex, Norderstedt, Germany). |
| Creatine kinase | At baseline and at week 9 (after the eight weeks of the training intervention). | Serum concentrations of creatine kinase are measured from a blood sample (5 ml) using a Beckman Coulter AU480 Chemistry Analyzer (France). |
| Lactate dehydrogenase | At baseline and at week 9 (after the eight weeks of the training intervention). | Serum concentrations of lactate dehydrogenase are measured from a blood sample (5 ml) using a Beckman Coulter AU480 Chemistry Analyzer (France). |
| Plasma volume variations | Plasma volume variations (PVV) was calculated after eight weeks under third conditions (High intensity training, Moderate intensity training and No training intervention [control group] ). | Plasma volume variations (PVV) was calculated based on measured hematocrit (Ht) and hemoglobin (Hb) values according to the method developed by Dill and Fink (1974). %PVV=100 ×\[(Hb0/Hb1) ×(100 - Ht1) / (100 - Ht0)\] - 1, where 0 is the value measured before training program and 1 is the value measured after training program. |
| Body weight | At baseline and after eight weeks of the training intervention. | Body weight (kg) was recorded , with barefoot and lightly dressed subjects, using an electronic scale (Tanita BC-533, Tokyo, Japan). |
| Height | At baseline and at week 9 (after the eight weeks of the training intervention). | Height (m) was determined using a standard stadiometer (Holtain Ltd., UK). |
| Body fat | At baseline and at week 9 (after the eight weeks of the training intervention). | Body fat (%) was recorded using an electronic scale (Tanita BC-533, Tokyo, Japan). |
| Body mass index | At baseline and at week 9 (after the eight weeks of the training intervention). | Body mass index (kg/m²) was calculated as weight (kg) divided by height squared (m²). |
| Waist circumference | At baseline and at week 9 (after the eight weeks of the training intervention). | Waist circumference (cm) was measured to the nearest 0.1 cm using a non-deformable anthropometric tape, placed horizontally at the midpoint between the inferior margin of the last palpable rib and the superior border of the iliac crest, with the participant standing upright and breathing normally. |
Countries
Tunisia
Outcome results
None listed